LUPIN LIMITED
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 176
- Registration Number
- NCT06549400
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 176
- Registration Number
- NCT06523400
A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05187858
- Locations
- 🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Belgium
🇳🇱Amsterdam UMC, Amsterdam, Netherlands
🇬🇧Sarah Cannon Research Institute, London, United Kingdom
Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Lupin Ltd.
- Registration Number
- NCT04700046
Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD
- Conditions
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT04690556
- Locations
- 🇮🇳
Mysore Medical College and Research Institute, Mysore, Karnataka, India
🇮🇳JSS Hospital, Mysore, Karnataka, India
🇮🇳Aakash Healthcare Super Specialty Hospital, New Delhi, India
Open Label Study in Adolescents and Children With Myotonic Disorders
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04624750
- Locations
- 🇫🇷
Hôpital Necker-Enfants-Malades, Paris, France
Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study.
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT04622553
- Locations
- 🇫🇷
Hôpital Necker-Enfants-Malades, Paris, France
An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders
- Conditions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT04616807
- Locations
- 🇫🇷
Hôpital Universitaire de La Pitié Salpêtrière, Paris, Cedex, France
🇫🇷CHRU Lille, Lille, France
🇩🇪Universitätsklinikum Ulm, Klinik für Neurologie, Ulm, Germany
Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 138
- Registration Number
- NCT03511378
- Locations
- 🇮🇳
Kailash Cancer Hospital & Research Center, Vadodara, Gujarat, India
🇮🇳M S Patel Cancer Centre,, Gokal, Anand, India
🇮🇳Sterling Hospital, Nigdi, Maharashtra, India
A Study to Test the Safety/Tolerability of Increasing Doses of LNP1892 Versus Placebo in Healthy Male/Female Subjects
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02174237
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd. Springfield House Hyde Street, Leeds, United Kingdom